Weak Immunogenicity In Patients With Cancer After First Dose Of MRNA-Based COVID-19 Vaccine

Published by W Butcher on

In a study conducted by Dr Romain Palich of the Medical Oncology department, Pitié-Salpêtrière hospital in Paris, France and colleagues almost half patients with cancer showed no anti-spike antibody response after a first injection of BNT162b2 (Pfizer-BioNTech) vaccine, and this low seroconversion rate was much worse in elderly patients and in those under chemotherapy. Moreover, even in patients with seroconversion, the level of antibody response was lower than expected. Findings from the study on antibody response 4 weeks after the first injection of the BNT162b2 vaccine in patients with cancer and healthcare workers as the control population were published on 28 April 2021 in the Annals of Oncology.

Read More…

Categories: Uncategorized